CompletedEUCTR 2018-001064-30

A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders

This historical record does not confirm current site availability.

Historical research recordBulgariaMental health

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Bulgaria
Study phase: Phase 1

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 36
Sponsor: ACADIA Pharmaceuticals Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Bulgaria
Age range: Not clearly listed
Official registry ID: EUCTR 2018-001064-30
Official title: Show the full official title
A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bulgaria

Registry details

Historical country statuses

Bulgaria — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Want to explore more studies?

Explore studies